These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 17040892)

  • 1. UK consultant rheumatologists' access to biological agents and views on the BSR Biologics Register.
    Kay LJ; Griffiths ID;
    Rheumatology (Oxford); 2006 Nov; 45(11):1376-9. PubMed ID: 17040892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry.
    Brennan A; Bansback N; Nixon R; Madan J; Harrison M; Watson K; Symmons D
    Rheumatology (Oxford); 2007 Aug; 46(8):1345-54. PubMed ID: 17562686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rheumatologists' judgements about the efficacy of anti-TNF therapy in two neighbouring regions.
    Kee F; Sheehy N; O'Hare L; Bane C; Bell A; Dempster M; FitzGerald O
    Rheumatology (Oxford); 2005 Nov; 44(11):1407-13. PubMed ID: 16030081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eligibility of rheumatoid arthritis patients for anti-TNF-alpha therapy according to the 2005 recommendations of the French and British Societies for Rheumatology.
    Fautrel B; Flipo RM; Saraux A
    Rheumatology (Oxford); 2008 Nov; 47(11):1698-703. PubMed ID: 18794185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.
    Dixon WG; Watson K; Lunt M; Hyrich KL; Silman AJ; Symmons DP;
    Arthritis Rheum; 2006 Aug; 54(8):2368-76. PubMed ID: 16868999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire.
    Barra L; Pope JE; Payne M
    J Rheumatol; 2009 Jul; 36(7):1421-8. PubMed ID: 19487267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice.
    Vander Cruyssen B; Ribbens C; Boonen A; Mielants H; de Vlam K; Lenaerts J; Steinfeld S; Van den Bosch F; Dewulf L; Vastesaeger N
    Ann Rheum Dis; 2007 Aug; 66(8):1072-7. PubMed ID: 17261531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The persistence of golimumab compared to other tumour necrosis factor-α inhibitors in daily clinical practice for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: observations from the Slovenian nation-wide longitudinal registry of patients treated with biologic disease-modifying antirheumatic drugs-BioRx.si.
    Rotar Ž; Tomšič M; Praprotnik S;
    Clin Rheumatol; 2019 Feb; 38(2):297-305. PubMed ID: 30324406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patients' perceptions of treatment with anti-TNF therapy for rheumatoid arthritis: a qualitative study.
    Marshall NJ; Wilson G; Lapworth K; Kay LJ
    Rheumatology (Oxford); 2004 Aug; 43(8):1034-8. PubMed ID: 15150436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Working status in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: results from the British Society for Rheumatology Biologics Register.
    Verstappen SM; Watson KD; Lunt M; McGrother K; Symmons DP; Hyrich KL;
    Rheumatology (Oxford); 2010 Aug; 49(8):1570-7. PubMed ID: 20444856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study.
    Heiberg MS; Koldingsnes W; Mikkelsen K; Rødevand E; Kaufmann C; Mowinckel P; Kvien TK
    Arthritis Rheum; 2008 Feb; 59(2):234-40. PubMed ID: 18240258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register.
    Dixon WG; Watson KD; Lunt M; Mercer LK; Hyrich KL; Symmons DP; ;
    Arthritis Care Res (Hoboken); 2010 Jun; 62(6):755-63. PubMed ID: 20535785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prevalence of patients with rheumatoid arthritis in the West Midlands fulfilling the BSR criteria for anti-tumour necrosis factor therapy: an out-patient study.
    Yee CS; Filer A; Pace A; Douglas K; Situnayake D; Rowe IF;
    Rheumatology (Oxford); 2003 Jul; 42(7):856-9. PubMed ID: 12730544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of the British Society for Rheumatology Biologics Register (BSRBR) and the NICE guidelines for anti-TNF therapy.
    Watson K; Hyrich K
    Musculoskeletal Care; 2003 Mar; 1(1):58-64. PubMed ID: 20217664
    [No Abstract]   [Full Text] [Related]  

  • 16. Regional review of patients with psoriatic arthritis in secondary care in the West Midlands: prevalence, disease activity and eligibility for anti-tumour necrosis factor therapy.
    Bateman J; Cardy CM; Khan SY; Menon A; Obrenovic K; Rowe IF; Erb N
    Clin Exp Rheumatol; 2009; 27(6):935-9. PubMed ID: 20149308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Belgian rheumatologists' perception on eligibility of RA patients for anti-TNF treatment matches more closely Dutch rather than Belgian reimbursement criteria.
    Geens E; Geusens P; Vanhoof J; Berghs H; Praet J; Esselens G; Lens S; Dufour JP; Vandenberghe M; Van Mullem X; Westhovens R; Verschueren P
    Rheumatology (Oxford); 2009 May; 48(5):546-50. PubMed ID: 19254920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biologics and cardiovascular events in inflammatory arthritis: a prospective national cohort study.
    Lee JL; Sinnathurai P; Buchbinder R; Hill C; Lassere M; March L
    Arthritis Res Ther; 2018 Aug; 20(1):171. PubMed ID: 30086795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. British Society for Rheumatology Biologics Register.
    Silman A; Symmons D; Scott DG; Griffiths I
    Ann Rheum Dis; 2003 Nov; 62 Suppl 2(Suppl 2):ii28-9. PubMed ID: 14532144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How good is the coverage and how accurate are exposure data in the Swedish Biologics Register (ARTIS)?
    Wadström H; Eriksson JK; Neovius M; Askling J;
    Scand J Rheumatol; 2015; 44(1):22-8. PubMed ID: 25379815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.